Overview

A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Status:
Active, not recruiting
Trial end date:
2022-03-04
Target enrollment:
Participant gender:
Summary
The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with JIA from 2 years to less than 18 years old.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company